An application to market the product in the European Union has also been submitted, for which approval is expected in 2006.
Confidentiality agreements prevent GroPep from naming the specific product or company.
While this approval is not likely to generate significant revenue growth for GroPep, CEO Mr Bob Finder said that the approval is further evidence of the growing international recognition of the superiority of GroPep's Cell Culture Products in the manufacturing of certain biopharmaceutical products.
About GroPep
GroPep is a world leader in the development, manufacture and commercialisation of biologically active proteins for cell culture and biomedical research. The Company has an active biopharmaceutical development program that establishes proof of concept for products in humans and partners the later stages of product development and marketing with major pharmaceutical companies. GroPep is listed on the Australian Stock Exchange Limited (ASX code: GRO).
Further Information:
Mr Tony Mitchell
Chief Financial Officer/Investor Relations
Ph: +61 8 8354 7700
investorrelations@gropep.com.au